NASDAQ:PCRX

Pacira BioSciences News Headlines

$63.07
-3.27 (-4.93 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$60.72
Now: $63.07
$64.88
50-Day Range
$66.34
MA: $70.38
$74.45
52-Week Range
$33.47
Now: $63.07
$80.00
Volume1.01 million shs
Average Volume488,850 shs
Market Capitalization$2.77 billion
P/E Ratio22.21
Dividend YieldN/A
Beta1.27

Headlines

Pacira BioSciences (NASDAQ PCRX) News Headlines Today

SourceHeadline
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Berenberg BankPacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Berenberg Bank
marketbeat.com - April 9 at 7:40 AM
Insider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells 21,823 Shares of StockInsider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells 21,823 Shares of Stock
americanbankingnews.com - April 15 at 10:32 PM
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Buy" from BrokeragesPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - April 15 at 2:34 PM
Pacira BioSciences (NASDAQ:PCRX) Receives New Coverage from Analysts at Berenberg BankPacira BioSciences (NASDAQ:PCRX) Receives New Coverage from Analysts at Berenberg Bank
americanbankingnews.com - April 15 at 9:50 AM
Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in AnesthesiologyPacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology
finance.yahoo.com - April 14 at 7:51 PM
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Berenberg BankPacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Berenberg Bank
americanbankingnews.com - April 9 at 9:10 AM
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $67.49Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $67.49
americanbankingnews.com - April 7 at 10:42 AM
Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021
finance.yahoo.com - April 7 at 8:22 AM
$0.59 Earnings Per Share Expected for Pacira BioSciences, Inc. (NASDAQ:PCRX) This Quarter$0.59 Earnings Per Share Expected for Pacira BioSciences, Inc. (NASDAQ:PCRX) This Quarter
americanbankingnews.com - April 4 at 2:10 PM
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather SparinglyPacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly
finance.yahoo.com - March 30 at 2:45 PM
Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 3:27 PM
After a Label Expansion, Is This Under-the-Radar Biotech a Buy?After a Label Expansion, Is This Under-the-Radar Biotech a Buy?
fool.com - March 27 at 10:27 AM
Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL(R) (bupivacaine liposome injectable suspension) in Pediatric PatientsPacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL(R) (bupivacaine liposome injectable suspension) in Pediatric Patients
marketwatch.com - March 23 at 9:34 AM
Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric PatientsPacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients
finance.yahoo.com - March 22 at 7:42 PM
After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to shareAfter winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share
msn.com - March 16 at 1:06 PM
Stocks Showing Leadership: Covid Recovery Play Ligand Earns Key Rating JumpStocks Showing Leadership: Covid Recovery Play Ligand Earns Key Rating Jump
finance.yahoo.com - March 15 at 3:01 PM
Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021
finance.yahoo.com - March 9 at 8:30 AM
Pacira BioSciences to Present at the 2021 Barclays Global Healthcare ConferencePacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference
finance.yahoo.com - March 3 at 7:40 AM
Pacira Pharmaceuticals Getting Closer To Key Technical MeasurePacira Pharmaceuticals Getting Closer To Key Technical Measure
finance.yahoo.com - February 23 at 5:18 PM
Pacira to Report 2020 Financial Results on Thursday February 25, 2021Pacira to Report 2020 Financial Results on Thursday February 25, 2021
finance.yahoo.com - February 18 at 8:54 AM
Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021
finance.yahoo.com - February 10 at 7:58 AM
Pacira BioSciences Inc.Pacira BioSciences Inc.
wsj.com - February 2 at 8:04 PM
Heres Why I Think Pacira BioSciences (NASDAQ:PCRX) Is An Interesting StockHere's Why I Think Pacira BioSciences (NASDAQ:PCRX) Is An Interesting Stock
finance.yahoo.com - January 29 at 1:01 PM
Pacira BioSciences Announces Equity Investment in GeneQuine BiotherapeuticsPacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
markets.businessinsider.com - January 26 at 9:19 AM
Pacira BioSciences Announces Equity Investment in GeneQuine BiotherapeuticsPacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
finance.yahoo.com - January 26 at 9:19 AM
PCRX Jan 2021 65.000 putPCRX Jan 2021 65.000 put
uk.finance.yahoo.com - January 17 at 12:50 AM
Pacira Reports Record Revenue for 2020 of $429.6 MillionPacira Reports Record Revenue for 2020 of $429.6 Million
finance.yahoo.com - January 7 at 7:45 AM
Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare ConferencePacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 10:27 AM
PCRX Jan 2021 52.500 putPCRX Jan 2021 52.500 put
uk.finance.yahoo.com - December 30 at 10:14 PM
Pacira BioSciences (NASDAQ:PCRX) Shareholders Booked A 38% Gain In The Last Three YearsPacira BioSciences (NASDAQ:PCRX) Shareholders Booked A 38% Gain In The Last Three Years
finance.yahoo.com - December 15 at 9:58 AM
Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020
finance.yahoo.com - December 9 at 7:45 AM
PCRX Dec 2020 57.500 putPCRX Dec 2020 57.500 put
uk.finance.yahoo.com - November 25 at 11:47 PM
PCRX Dec 2020 65.000 putPCRX Dec 2020 65.000 put
uk.finance.yahoo.com - November 25 at 6:47 PM
PCRX Dec 2020 52.500 callPCRX Dec 2020 52.500 call
uk.finance.yahoo.com - November 25 at 6:47 PM
PCRX Dec 2020 50.000 putPCRX Dec 2020 50.000 put
uk.finance.yahoo.com - November 25 at 12:10 AM
PCRX Dec 2020 67.500 callPCRX Dec 2020 67.500 call
uk.finance.yahoo.com - November 24 at 7:10 PM
Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare ConferencePacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 24 at 9:08 AM
Pacira Receives European Commission Approval for EXPAREL(R) (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical PainPacira Receives European Commission Approval for EXPAREL(R) (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
marketwatch.com - November 19 at 7:53 PM
Paciras postsurgical pain med Okd in EuropePacira's postsurgical pain med Ok'd in Europe
seekingalpha.com - November 18 at 8:47 AM
Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical PainPacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
finance.yahoo.com - November 18 at 8:47 AM
Dow Jones Rises 330 Points To Record High On Positive Vaccine DataDow Jones Rises 330 Points To Record High On Positive Vaccine Data
finance.yahoo.com - November 16 at 2:20 PM
Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating BenchmarkPacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - November 13 at 12:51 PM
Pacira BioSciences reports October net product salesPacira BioSciences reports October net product sales
seekingalpha.com - November 11 at 1:55 PM
Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020
finance.yahoo.com - November 11 at 1:55 PM
IBD 50 Stocks To Watch: This Pharma Stock On 115% Run Eyes Buy PointIBD 50 Stocks To Watch: This Pharma Stock On 115% Run Eyes Buy Point
finance.yahoo.com - November 11 at 1:55 PM
Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare ConferencePacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 10:35 AM
Pacira BioSciences, Inc.s (NASDAQ:PCRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
finance.yahoo.com - November 9 at 1:34 PM
Pacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Call TranscriptPacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Call Transcript
finance.yahoo.com - October 30 at 8:59 AM
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call TranscriptPacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - October 29 at 6:54 PM
Pacira BioSciences, Inc. (PCRX)Pacira BioSciences, Inc. (PCRX)
au.finance.yahoo.com - October 29 at 1:53 PM
Pacira BioSciences EPS beats by $0.03, beats on revenuePacira BioSciences EPS beats by $0.03, beats on revenue
seekingalpha.com - October 29 at 1:53 PM
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.